Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
Brianna L Combs, Arthur G Cox Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA Abstract: Parkinson’s disease (PD) has a prevalence of nearly 1 million people in the USA, with increasing incidence in the elderly population. Generally, the...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e813b878a83e45f79426936c56c945e5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e813b878a83e45f79426936c56c945e5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e813b878a83e45f79426936c56c945e52021-12-02T07:17:59ZUpdate on the treatment of Parkinson’s disease psychosis: role of pimavanserin1178-2021https://doaj.org/article/e813b878a83e45f79426936c56c945e52017-03-01T00:00:00Zhttps://www.dovepress.com/update-on-the-treatment-of-parkinsonrsquos-disease-psychosis-role-of-p-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Brianna L Combs, Arthur G Cox Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA Abstract: Parkinson’s disease (PD) has a prevalence of nearly 1 million people in the USA, with increasing incidence in the elderly population. Generally, the age of presentation is between 55 and 65 years, with the likelihood of diagnosis increasing as patients reach the age of 80 years or above. Some of the common treatments for PD increase dopamine levels in the brain. Dopaminergic therapy helps to improve motor and non-motor symptoms, but it is not without risks. Dopaminergic therapy can cause confusion, delirium, and psychotic-like behavior. It is recommended that these agents are used cautiously in patients with a history of psychosis due to the risk of exacerbation. It is unclear whether Parkinson’s disease psychosis (PDP) is due to the disease itself, the treatment, or a combination of both, but it is clear that a safe, effective treatment is necessary. Second-generation (atypical) antipsychotics are the current choice of therapy for PDP. All of these agents have a black box warning from the US Food and Drug Administration (FDA) for elevated risk of mortality in elderly patients with dementia-related psychosis. Pimavanserin (Nuplazid®) received its novel drug approval by the FDA on April 29, 2016, to treat hallucinations and delusions associated with psychosis experienced by some people with PD. We review in this article the new research that led to this approval as well as its potential place in therapy. Keywords: pimavanserin, Parkinson’s disease psychosis, Parkinson’s diseaseCombs BLCox AGDove Medical PressarticleParkinson's DiseasePsychosisPimavanserinNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 737-744 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Parkinson's Disease Psychosis Pimavanserin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Parkinson's Disease Psychosis Pimavanserin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Combs BL Cox AG Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| description |
Brianna L Combs, Arthur G Cox Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA Abstract: Parkinson’s disease (PD) has a prevalence of nearly 1 million people in the USA, with increasing incidence in the elderly population. Generally, the age of presentation is between 55 and 65 years, with the likelihood of diagnosis increasing as patients reach the age of 80 years or above. Some of the common treatments for PD increase dopamine levels in the brain. Dopaminergic therapy helps to improve motor and non-motor symptoms, but it is not without risks. Dopaminergic therapy can cause confusion, delirium, and psychotic-like behavior. It is recommended that these agents are used cautiously in patients with a history of psychosis due to the risk of exacerbation. It is unclear whether Parkinson’s disease psychosis (PDP) is due to the disease itself, the treatment, or a combination of both, but it is clear that a safe, effective treatment is necessary. Second-generation (atypical) antipsychotics are the current choice of therapy for PDP. All of these agents have a black box warning from the US Food and Drug Administration (FDA) for elevated risk of mortality in elderly patients with dementia-related psychosis. Pimavanserin (Nuplazid®) received its novel drug approval by the FDA on April 29, 2016, to treat hallucinations and delusions associated with psychosis experienced by some people with PD. We review in this article the new research that led to this approval as well as its potential place in therapy. Keywords: pimavanserin, Parkinson’s disease psychosis, Parkinson’s disease |
| format |
article |
| author |
Combs BL Cox AG |
| author_facet |
Combs BL Cox AG |
| author_sort |
Combs BL |
| title |
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| title_short |
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| title_full |
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| title_fullStr |
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| title_full_unstemmed |
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin |
| title_sort |
update on the treatment of parkinson’s disease psychosis: role of pimavanserin |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/e813b878a83e45f79426936c56c945e5 |
| work_keys_str_mv |
AT combsbl updateonthetreatmentofparkinsonrsquosdiseasepsychosisroleofpimavanserin AT coxag updateonthetreatmentofparkinsonrsquosdiseasepsychosisroleofpimavanserin |
| _version_ |
1718399551560220672 |